Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.53 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191612 | 0.86 | EGFR (0.52) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL29693649 | 0.80 | EGFR (0.73) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL141514 | 0.80 | EGFR (0.73) | EGFRERBB2ERBB4ERBB3GAK | |
| Hydrochloric Acid SCHEMBL215037 | 0.79 | EGFR (0.72) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL17075799 | 0.77 | EGFR (0.70) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL3323388 | 0.77 | EGFR (0.49) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL31069021 | 0.75 | EGFR (0.75) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL3897439 | 0.75 | EGFR (0.75) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL19089647 | 0.74 | EGFR (0.63) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL13362689 | 0.74 | CDK2 (0.48) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664389-B2 | Process for the preparation of lapatinib and it's pharmaceutically acceptable salts | NATCO PHARMA LIMITED (IN) | 2014-03-04 | — | — | US | disclosed |
| US-20120245351-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2012-09-27 | — | — | US | disclosed |
| US-20110263852-A1 | NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2358666-A1 | A NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Natco Pharma Limited (IN) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011039759-A1 | A NEW PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010061400-A1 | A NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245351-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ABL1, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20110263852-A1 | NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ABL1, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.